摘要
目的探讨不同级别胶质瘤中P53、EGFR、Ki-67及MGMT的表达及临床意义。方法应用免疫组织化学方法检测152例胶质瘤中P53、EGFR、Ki-67及MGMT表达,统计分析上述蛋白的表达差异。结果 P53在Ⅱ、Ⅲ、Ⅳ级胶质瘤中阳性率分别为71.4%,73.1%和60.0%。95例EGFR阳性,其阳性表达率与染色强度均与病理级别呈正相关(P<0.01)。Ki-67均为阳性表达,Ki-67LI在高级别胶质瘤中明显高于其在低级别胶质瘤中的表达水平(P<0.01)。MGMT阳性84例,阴性68例,在低级别胶质瘤和高级别胶质瘤之间的MGMT表达无明显差异(P>0.05)。结论 EGFR和Ki-67表达与肿瘤病理级别呈正相关,与胶质瘤恶性进展及预后差密切相关。P53和MGMT与肿瘤病理级别无明显相关性。检测有助于评估胶质瘤侵袭能力、增殖性,预测胶质瘤对放、化疗敏感性及判断分子靶向药物治疗是否有效。
Objective To investigate the expression and clinical significance of P53,EGFR, Ki67 and MGMT in different grade gliomas. Methods The expressions of P53, Ki-67, EGFR and MGMT proteins in different grade gliomas were assayed by immunohistochemistry and expression differences were analyzed statistically. Results The positive rates of P53 were 71.4% ,73.1% and 60.0% in grade II - IV. ECFR protein is positive in 95 cases, its positive expression rate and staining intensity were positively correlated with the pathological grade（P 〈 0.01 ）. Ki-67 express in all different grades of glioma and the expression level was increased grade （ P 〈 0. 01 ）. MGMT expressions is positive in 84 cases and negative in 68. The expression did not correlate with grade （P 〉 0. 05 ）. Conclusions The expression of EGFR and Ki-67 are significantly correlate with the WHO classification of glioma, EGFR and Ki-67 are significantly associated with malignant progression and poor prognosis. P53 and MGMT have no correlation with grades of glioma. Detection can help to assess the ability of invasion, proliferation, prediction of glioma to radiotherapy and chemotherapy sensitivity and to determine the effectiveness of mo]ecular targeted therapy.
出处
《临床神经外科杂志》
CAS
2011年第4期187-189,共3页
Journal of Clinical Neurosurgery
基金
南京市医学科技发展资金资助项目(ZKX10021)
关键词
胶质瘤
免疫组化
病理
glioma
immunohistochemistry
pathology
